Lu Yang, Zhao Ning, Du Yimei
Department of Cardiology, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, China.
Research Center of Ion Channelopathy, Tongji Medical College, Union Hospital, Huazhong University of Science and Technology, Wuhan, China.
Front Cardiovasc Med. 2022 Oct 24;9:1027026. doi: 10.3389/fcvm.2022.1027026. eCollection 2022.
Atrial fibrillation (AF) is the most common arrhythmia in coronary virus disease 2019 (COVID-19) patients, especially in severe patients. A history of AF can exacerbate COVID-19 symptoms. COVID-19 Patients with new-onset AF have prolonged hospital stays and increased death risk. However, the mechanisms and targets of the interaction between COVID-19 and AF have not been elucidated.
We used a series of bioinformatics analyses to understand biological pathways, protein-protein interaction (PPI) networks, gene regulatory networks (GRNs), and protein-chemical interactions between COVID-19 and AF and constructed an AF-related gene signature to assess COVID-19 severity and prognosis.
We found folate and one-carbon metabolism, calcium regulation, and TFG-β signaling pathway as potential mechanisms linking COVID-19 and AF, which may be involved in alterations in neutrophil metabolism, inflammation, and endothelial cell function. We identified hug genes and found that NF-κb, hsa-miR-1-3p, hsa-miR-124-3p, valproic acid, and quercetin may be key regulatory molecules. We constructed a 3-gene signature consisting of ARG1, GIMAP7, and RFX2 models for the assessment of COVID-19 severity and prognosis, and found that they are associated with neutrophils, T cells, and hematopoietic stem cells, respectively.
Our study reveals a dysregulation of metabolism, inflammation, and immunity between COVID-19 and AF, and identified several therapeutic targets and progression markers. We hope that the results will reveal important insights into the complex interactions between COVID-19 and AF that will drive novel drug development and help in severity assessment.
心房颤动(AF)是2019年冠状病毒病(COVID-19)患者中最常见的心律失常,尤其是在重症患者中。房颤病史会加重COVID-19症状。新发房颤的COVID-19患者住院时间延长,死亡风险增加。然而,COVID-19与房颤之间相互作用的机制和靶点尚未阐明。
我们使用了一系列生物信息学分析来了解COVID-19与房颤之间的生物途径、蛋白质-蛋白质相互作用(PPI)网络、基因调控网络(GRN)和蛋白质-化学相互作用,并构建了一个与房颤相关的基因特征来评估COVID-19的严重程度和预后。
我们发现叶酸和一碳代谢、钙调节以及转化生长因子-β信号通路是连接COVID-19与房颤的潜在机制,这可能与中性粒细胞代谢、炎症和内皮细胞功能的改变有关。我们鉴定出了枢纽基因,发现核因子-κB、hsa-miR-1-3p、hsa-miR-124-3p、丙戊酸和槲皮素可能是关键调控分子。我们构建了一个由精氨酸酶1(ARG1)、GIMAP家族成员7(GIMAP7)和调节因子X2(RFX2)组成的三基因特征模型来评估COVID-19的严重程度和预后,发现它们分别与中性粒细胞、T细胞和造血干细胞有关。
我们的研究揭示了COVID-19与房颤之间代谢、炎症和免疫的失调,并确定了几个治疗靶点和病情进展标志物。我们希望这些结果将揭示COVID-19与房颤之间复杂相互作用的重要见解,从而推动新型药物的开发并有助于严重程度评估。